Table 1.
Patient characteristics at enrollment in the Longitudinal Study of the Ocular Complications of AIDS cohort
| Enrollment Cohort | |||||
|---|---|---|---|---|---|
| 1998–2002 | 2003–2005 | 2006–2012 | Total | P-valuea | |
| Number patients | 1180 | 329 | 380 | 1889 | |
| Median age, years (25th, 75th percentile) | 42 (37,47) | 44 (40,51) | 46 (40, 52) | 43 (38, 49) | < 0.0001 |
| Male (%) | 81 | 77 | 80 | 80 | 0.36 |
| Race (%) | < 0.0001 | ||||
| White | 50 | 34 | 39 | 45 | |
| African American | 33 | 45 | 48 | 38 | |
| Other | 17 | 20 | 13 | 17 | |
| HIV transmission category (%) | 0.02 | ||||
| Male to male sexual contact | 57 | 48 | 51 | 54 | |
| Injection drug useb | 12 | 18 | 16 | 14 | |
| Other | 31 | 34 | 33 | 32 | |
| Any insurance (%) | 82 | 89 | 84 | 83 | 0.08 |
| Median time since AIDS diagnosis, years (25th, 75th percentile) | 4.0 (1.6,6.4) | 5.5 (1.7,8.7) | 4.7 (1.1, 8.2) | 4.3 (1.6, 7.2) | < 0.0001 |
| AIDS diagnosis category (%) | 0.001 | ||||
| CD4+ T-cell lymphopenia | 64 | 62 | 74 | 65 | |
| Opportunistic infection or malignancy | 32 | 34 | 23 | 31 | |
| Enrollment CD4+ T-cells (cells/uL) | |||||
| Median(25th, 75th percentile) | 174 (66,325) | 197 (104,380) | 282 (124,427) | 197 (80,358) | < 0.0001 |
| Percent participants <200 | 55 | 50 | 37 | 51 | <0.0001 |
| Percent participants 200–500 | 34 | 35 | 44 | 36 | |
| Percent participants >500 | 11 | 14 | 19 | 13 | |
| Nadir CD4+ T-cells (cells/uL) | |||||
| Median (25th, 75th percentile) | 43 (13,112) | 44 (14,101) | 50 (16,133) | 44 (14,115) | 0.29 |
| Percent participants <50 | 53 | 53 | 50 | 53 | 0.24 |
| Percent participants ≥50 | 47 | 47 | 40 | 47 | |
| Enrollment HIV load (log10[copies/mL]) | |||||
| Median (25th, 75th percentile) | 3.3 (2.4,4.8) | 2.6 (1.9,4.4) | 2.0 (1.7,2.7) | 2.7 (1.9,4.6) | < 0.0001 |
| Percent participants <2.6 | 27 | 42 | 63 | 37 | < 0.0001 |
| Percent participants 2.6–5 | 32 | 29 | 20 | 29 | |
| Percent participants ≥ 5 | 40 | 29 | 17 | 33 | |
| Maximum prior HIV load (log10copies/ml) | |||||
| Median (25th, 75th percentile) | 5.3 (4.7,5.7) | 5.3 (4.7,5.8) | 5.3 (4.8,5.7) | 5.3 (4.7,5.7) | 0.63 |
| Percent participants <5 | 11 | 11 | 10 | 11 | 0.38 |
| Percent participants ≥5 | 89 | 89 | 90 | 90 | |
| Antiretroviral therapy (%) | |||||
| Any ART prior to enrollmentc | 76 | 83 | 94 | 81 | < 0.0001 |
| Receiving cART at enrollmentc | 82 | 88 | 92 | 85 | < 0.0001 |
| Any cART during follow-upc | 96 | 96 | 97 | 97 | 0.14 |
a
P-values comparing three cohorts.
b
Injection drug use category includes persons with any injection drug use.
c
ART = antiretroviral therapy. cART = combination antiretroviral therapy (see Methods).